The primary outcome of the study was a composite measure of "organ support-free days," representing the number of days patients remained alive and without the need for respiratory or cardiovascular organ support in the intensive care unit up to day 21, along with survival to hospital discharge. The study revealed that vitamin C administered according to the described protocol had a very low probability of improving the primary outcome in both the critically ill and non-critically ill patient groups. Specifically, among critically ill patients, no significant improvements in organ support-free days were observed between the vitamin C group and the control group. Among non-critically ill patients, vitamin C did not significantly affect the primary outcome or hospital survival. In conclusion, this study suggests that administering vitamin C at a dose of 50 mg/kg of body weight via intravenous infusion every 6 hours for 96 hours does not appear to have a significant impact on improving the recovery and survival of hospitalized patients with COVID-19, regardless of whether they were critically ill or not. The full article is available at: Intravenous Vitamin C for Patients Hospitalized With COVID-19.